Sign in to view content

Episode 25: RIVAL Study: Ranibizumab vs Aflibercept in T&E for wet AMD with Dr. Mark Gillies

Keyvan Koushan, MD, FRCSC

Audio
Published 2019

Related

Novel Vascular Endothelial Growth-Factor A (VEGF-A) and Angiopoietin-2 (Ang-2) Bispecific Protein, RO-634, in Comparison to Aflibercept
Mark R. Barakat, MD
Annual Meeting Talks
2022
ENVISION Trial 24-Week Data: Phase 2 Study of UBX1325, a New Senolytic Agent for Patients With Wet AMD
Raj K. Maturi, MD
Annual Meeting Talks
2023
Learnings From the Lampalizumab Chroma and Spectri Phase 3 Trials: Effect of Baseline Characteristics on Geographic Atrophy Progression
Carl D. Regillo, MD
Annual Meeting Talks
2018

Category: Age-Related Macular Degeneration

See more